Vol 45, No 1 (2007)
Original paper
Published online: 2007-03-24

open access

Page views 1304
Article views/downloads 1501
Get Citation

Connect on Social Media

Connect on Social Media

Thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood.

Waldemar Uszyński, Mieczysław Uszyński, Ewa Zekanowska, Krzysztof Góralczyk
Folia Histochem Cytobiol 2007;45(1):33-36.

Abstract

Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogene (procarboxypeptidase B) which can decrease fibrinolysis and thus act as a haemostatic factor. TAFI is now extensively studied in many complications as well as in physiological and complicated pregnancy. The question we posed in the present study was whether TAFI antigen is present in cord blood plasma. The study group consisted of 38 parturient women, 26 primiparous and 12 multiparous with normal course of pregnancy and delivery. The cord blood was sampled from the cord vein, and the mother's blood from the antecubital vein. 3.2% sodium citrate was used as an anticoagulant. TAFIa/ai antigen was measured by ELISA method. TAFIa/ai antigen was identified in all samples of cord blood plasma. Its level was 91.50 ng/ml (range: 71.76 - 160.77 ng/ml) vs. 55.46 ng/ml (range: 39.77 - 68.54 ng/ml ) in the mother's blood, which means that the level of TAFIa/ai antigen was significantly higher in fetal blood than in maternal blood (p<0.00001). TAFIa/ai antigen is an integral component of cord blood plasma. The concentration of TAFIa/ai antigen is about two times higher in fetal blood than in maternal blood.

Article available in PDF format

View PDF Download PDF file